SOBHANI, NAVID

SOBHANI, NAVID  

Dipartimento Universitario Clinico di Scienze mediche, chirurgiche e della salute  

Mostra records
Risultati 1 - 20 di 36 (tempo di esecuzione: 0.041 secondi).
Titolo Data di pubblicazione Autori File
Advances in systemic therapy for malignant mesothelioma: Future perspectives 1-gen-2017 Sobhani, NavidCorona, Silvia PaolaBonazza, DeborahIanza, AnnaRoviello, GiandomenicoCortale, MaurizioGuglielmi, AlessandraZanconati, FabrizioGenerali, Daniele +
Advances in systemic therapy for metastatic breast cancer: future perspectives 1-gen-2017 Corona, S. P.SOBHANI, NAVIDIANZA, ANNAROVIELLO, GIANDOMENICOMUSTACCHI, GIORGIOBORTUL, MARINAZANCONATI, FABRIZIOGENERALI, DANIELE
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 1-gen-2023 Sobhani, NavidAldegheri, GiovanniRocca, AndreaGiudici, FabiolaBottin, CristinaZanconati, FabrizioGenerali, Daniele +
Avelumab in gastric cancer 1-gen-2019 Roviello G.Generali D.De Manzini N.Sobhani N. +
Bevacizumab in small cell lung cancer 1-gen-2017 Roviello, GiandomenicoSobhani, NavidGenerali, Daniele
Cancer management during the COVID-19 world pandemic 1-gen-2023 Navid SobhaniGiandomenico RovielloBruna ScaggianteDaniele Generali +
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 1-gen-2018 Navid SobhaniDaniele GeneraliFabrizio ZanconatiMarina BortulBruna Scaggiante
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study 1-gen-2022 Giudici, FabiolaSobhani, NavidGenerali, Daniele +
Corticosteroid switch after progression on abiraterone acetate plus prednisone 1-gen-2020 Roviello G.Sobhani N.Corona S. +
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy 1-gen-2021 Sobhani, NavidGenerali, Daniele +
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 1-gen-2018 Sobhani, NavidGenerali, DanieleRoviello, Giandomenico +
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 1-gen-2018 Sobhani, NavidIanza, AnnaRoviello, GiandomenicoGiudici, FabiolaBortul, MarinaZanconati, FabrizioBottin, CristinaGenerali, Daniele +
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 1-gen-2018 Navid SobhaniDaniele GeneraliFabrizio ZanconatiMarina BortulBruna Scaggiante
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 1-gen-2017 SOBHANI, NAVIDCorona, Silvia PZANCONATI, FABRIZIOGENERALI, DANIELE
Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer 1-gen-2020 Bernocchi O.Sobhani N.Giudici F.Generali D. +
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair 1-gen-2023 Navid SobhaniSergio CrovellaFabrizio ZanconatiCristina BottinMarco ConfalonieriDaniele Generali +
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 1-gen-2017 Sobhani, N.Ianza, A.Roviello, G.Mustacchi, G.Bortul, M.Zanconati, F.Generali, D. +
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study 1-gen-2020 Sobhani, NavidIanza, AnnaBernocchi, OttaviaGiudici, FabiolaGenerali, Daniele +
Immune-gene signature: A new tool for patient selection for checkpoint inhibitors? 1-gen-2020 Sobhani N.Roviello G.Generali D. +
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses 1-gen-2023 Generali, DanieleSobhani, NavidBonazza, Debora +